# Study of Olverembatinib (HQP1351) in Patients With CML-CP

Source: https://onco.cc/trials/nct06423911/  
OnCo record `nct06423911` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.

## Summary

Study of Olverembatinib (HQP1351) in Patients With CML-CP is a phase 3 interventional study registered as NCT06423911 by Ascentage Pharma Group Inc., with 333 participants planned, started 2024-02-05. Conditions listed: Chronic Myeloid Leukemia, CML, CML, Chronic Phase. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06423911
- Phase: 3
- Setting: A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 333

## Sources

- ClinicalTrials.gov NCT06423911: https://clinicaltrials.gov/study/NCT06423911

## Connected records

- drugs: [Olverembatinib](https://onco.cc/drugs/olverembatinib/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06423911.json